LabTube is no longer active

LabTube is no longer accepting new video uploads, and will shortly be rolled down.

On our parent publication, Technology Networks, you’ll be able to find videos covering a range of topics across the life sciences, applied markets, analytical sciences, drug discovery and more. Click here to learn more.

Paper Spotlight: Bacterial Therapy Experiments in Prostate Cancer



November 2, 2021

  • Share
  • Oncotarget published this trending research paper on November 3, 2020, entitled, "Evaluations of CRC2631 toxicity, tumor colonization, and genetic stability in the TRAMP prostate cancer model" by researchers from the Cancer Research Center, Columbia, MO; Department of Immunobiology, Yale University, New Haven, CT; Department of Radiology and Department of Physics and Astronomy, University of Missouri, Columbia, MO; Research Service, Harry S. Truman Memorial Veterans Hospital, Columbia, MO; Department of Psychological Sciences, Institute for Data Science & Informatics, University of Missouri, Columbia, MO; Department of Biology, DeSales University, Center Valley, PA; Division of Biological Sciences, University of Missouri, Columbia, MO. Abstract: Conventional cancer chemotherapies are not fully efficacious and do not target tumors, leading to significant treatment-related morbidities. A number of genetically attenuated cancer-targeting bacteria are being developed to safely target tumors in vivo. Here we report the toxicological, tumor-targeting, and efficacy profiles of Salmonella enterica serovar Typhimurium CRC2631 in a syngeneic and autochthonous TRAMP model of aggressive prostate cancer. CRC2631 preferentially colonize primary and metastatic tumors in the TRAMP animals. In addition, longitudinal whole genome sequencing studies of CRC2631 recovered from prostate tumor tissues demonstrate that CRC2631 is genetically stable. Moreover, tumor-targeted CRC2631 generates an anti-tumor immune response. Combination of CRC2631 with checkpoint blockade reduces metastasis burden. Collectively, these findings demonstrate a potential for CRC2631 in cancer immunotherapy strategies. Press release - Sign up for free Altmetric alerts about this article - DOI - Full text - Correspondence to - Yves C. Chabu - Keywords - salmonella, cancer targeting, prostate cancer, immunotherapy, TRAMP About Oncotarget Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit or connect with: SoundCloud - Facebook - Twitter - Instagram - YouTube - LinkedIn - Pinterest - Reddit - Oncotarget is published by Impact Journals, LLC please visit or connect with @ImpactJrnls Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

    BioengineeringCancer ResearchCell ScienceImmunology

    Keep up to date with all your favourite videos and channels.

    Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.